Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 13/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.34 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.34 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.34 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2219998 | 0.92 | LMNA (0.44) | P2RX3NPSR1ALDH1A1LMNAMAPT | |
| SCHEMBL15887150 | 0.92 | NPSR1 (0.40) | P2RX3P2RX7NPSR1GUCY1B2GUCY1A2 | |
| SCHEMBL2217150 | 0.91 | NPSR1 (0.37) | P2RX3P2RX7NPSR1METGUCY1B2 | |
| SCHEMBL14554144 | 0.90 | GUCY1B2 (0.34) | P2RX3P2RX7NPSR1METGUCY1B2 | |
| SCHEMBL2218752 | 0.89 | NPSR1 (0.46) | P2RX3NPSR1ALDH1A1LMNAMAPT | |
| SCHEMBL2219260 | 0.88 | MEN1 (0.42) | P2RX3P2RX7NPSR1TRPA1MET | |
| SCHEMBL1580227 | 0.87 | P2RX3 (0.39) | P2RX3NPSR1ALDH1A1LMNAMAPT | |
| SCHEMBL2218317 | 0.87 | NPSR1 (0.39) | P2RX3NPSR1TRPA1METLMNA | |
| SCHEMBL15887168 | 0.85 | NPSR1 (0.41) | P2RX3P2RX7NPSR1ALDH1A1LMNA | |
| SCHEMBL12515493 | 0.85 | NPSR1 (0.38) | P2RX3NPSR1TRPA1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2310388-B1 | PYRIDOPYRIMIDINE COMPOUNDS AS ANTI-TUBERCULAR AGENTS | PASTEUR INSTITUT KOREA (KR) | 2015-08-05 | — | — | EP | claimed |
| US-8785452-B2 | Anti-infective compounds | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2014-07-22 | — | — | US | claimed |
| EP-2310388-B1 | PYRIDOPYRIMIDINE COMPOUNDS AS ANTI-TUBERCULAR AGENTS | PASTEUR INSTITUT KOREA (KR) | 2015-08-05 | — | — | EP | disclosed |
| EP-2310388-B1 | PYRIDOPYRIMIDINE COMPOUNDS AS ANTI-TUBERCULAR AGENTS | PASTEUR INSTITUT KOREA (KR) | 2015-08-05 | — | — | EP | disclosed |
| US-8785452-B2 | Anti-infective compounds | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2014-07-22 | — | — | US | disclosed |
| US-8785452-B2 | Anti-infective compounds | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2014-07-22 | — | — | US | disclosed |
| US-8785452-B2 | Anti-infective compounds | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2014-07-22 | — | — | US | disclosed |
| EP-2730576-A2 | Anti-infective compounds | Institut Pasteur Korea (KR) | 2014-05-14 | — | — | EP | disclosed |
| EP-2730576-A2 | Anti-infective compounds | Institut Pasteur Korea (KR) | 2014-05-14 | — | — | EP | disclosed |
| US-20130012506-A1 | ANTI-INFECTIVE PYRIDO (1,2-A) PYRIMIDINES | NO ZAESUNG (KR) | 2013-01-10 | — | — | US | disclosed |
| US-20130012506-A1 | ANTI-INFECTIVE PYRIDO (1,2-A) PYRIMIDINES | NO ZAESUNG (KR) | 2013-01-10 | — | — | US | disclosed |
| US-20130012506-A1 | ANTI-INFECTIVE PYRIDO (1,2-A) PYRIMIDINES | NO ZAESUNG (KR) | 2013-01-10 | — | — | US | disclosed |
| US-20110178077-A1 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178077-A1 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178077-A1 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2011-07-21 | — | — | US | disclosed |
| WO-2011085990-A1 | ANTI - INFECTIVE PYRIDO (1,2 -A) PYRIMIDINES | INSTITUT PASTEUR KOREA (KR) | 2011-07-21 | — | — | WO | disclosed |
| EP-2310388-A2 | PYRIDOPYRIMIDINE COMPOUNDS AS ANTI-TUBERCULAR AGENTS | Institut Pasteur Korea (KR) | 2011-04-20 | — | — | EP | disclosed |
| WO-2010003533-A2 | ANTI-INFECTIVE COMPOUNDS | INSTITUT PASTEUR KOREA (KR) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178077-A1 | Anti-infective compounds | RABGGTB, ELANE, SERPINB1 | P2RX3 3956/4885P2RX7 3868/4885NPSR1 4172/4885 |
| US-20130012506-A1 | ANTI-INFECTIVE PYRIDO (1,2-A) PYRIMIDINES | TYMS, TYMP, DCTPP1 | P2RX3 375/4885P2RX7 306/4885NPSR1 3987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.